Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Medexus licenses Zemcelpro for Canada
Business licensing agreement

Medexus licenses Zemcelpro for Canada

Analysis based on 6 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The licensing agreement between Medexus Pharmaceuticals, ExCellThera, and Cordex Biologics for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel's Canadian commercialization is expected to positively impact Medexus Pharmaceuticals's stock price due to the expansion of its innovative treatment portfolio. This partnership also creates long-term value for ExCellThera and Cordex Biologics through royalties and milestone payments, potentially attracting further investment in the biotechnology sector.

Pharmaceuticals Biotechnology
Event Summary

ExCellThera Inc. and its subsidiary Cordex Biologics have announced exclusive licensing and supply agreements with Medexus Pharmaceuticals, granting Medexus Pharmaceuticals the Canadian commercialization rights for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel (UM171 Cell Therapy). Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel is a novel personalized cryopreserved hematopoietic stem cell transplantation product used to treat hematological malignancies. While Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel has received conditional marketing authorization from the International — European Commission, Medexus Pharmaceuticals will seek Canada — Health Canada approval, with commercialization not expected before 2028. This partnership is a significant step in Cordex's global commercialization strategy for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, aiming to improve access to innovative therapies for Canadian patients with high-risk blood cancers. The transaction includes royalties on Canadian net sales and milestone payments, creating shared economic interest.

Key Actions
95 ExCellThera granted licensing agreements Medexus Pharmaceuticals
95 Cordex Biologics granted licensing agreements Medexus Pharmaceuticals
80 Medexus Pharmaceuticals intends seek approval Canada — Health Canada
70 International — European Commission granted marketing authorization Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel
Entities Involved
oth
Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel
Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel (UM171 Cell Therapy) is a novel personalized cryopreserved hematopoietic stem cell transplantation product for blood cancers, which has received conditional marketing authorization in Europe and is now subject to licensing agreements for Canadian commercialization.
Importance 100 Sentiment 75
stock
Medexus Pharmaceuticals
Medexus Pharmaceuticals has been granted exclusive Canadian commercialization rights for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, a novel cell therapy, which is expected to enhance its portfolio in hematology and oncology, pending Canada — Health Canada approval.
Importance 95 Sentiment 65
priv
ExCellThera
ExCellThera, a global leader in blood stem cell expansion, has granted exclusive licensing and supply agreements to Medexus Pharmaceuticals for the Canadian commercialization rights of Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, advancing its global commercialization strategy.
Importance 90 Sentiment 70
priv
Cordex Biologics
Cordex Biologics, a wholly owned subsidiary of ExCellThera, has granted exclusive licensing and supply agreements to Medexus Pharmaceuticals for the Canadian commercialization rights of Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, which includes royalties and milestone payments.
Importance 90 Sentiment 70
cnt
Canada
Canada is the country where Medexus Pharmaceuticals has secured exclusive commercialization rights for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, pending regulatory approval.
Importance 70 Sentiment 0
govactor
Canada — Health Canada
Canada — Health Canada is the regulatory body whose approval is required for Medexus Pharmaceuticals to begin commercializing Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel in Canada.
Importance 60 Sentiment 0
govactor
International — European Commission
The International — European Commission has already granted conditional marketing authorization for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel in Europe, indicating its potential.
Importance 50 Sentiment 0
per
David Millette
David Millette, CEO of Cordex Biologics, expressed the importance of the agreements with Medexus Pharmaceuticals for advancing Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel and improving patient access.
Importance 40 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration has granted orphan drug designation and regenerative medicine advanced therapy (RMAT) designations to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Importance 30 Sentiment 0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency has granted orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification, and priority medicines (PRIME) designation to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Importance 30 Sentiment 0
cnt
United States
The United States is one of the countries where Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel has been evaluated in clinical trials and where additional regulatory filings are planned.
Importance 20 Sentiment 0
cnt
United Kingdom
The United Kingdom is one of the countries where additional regulatory filings are planned for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Importance 20 Sentiment 0
cnt
Switzerland
Switzerland is one of the countries where additional regulatory filings are planned for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.